Table 1.
Clinical, biological, and pathological characteristics of the 115 HNSCC patients, and their associations with PFS
| Characteristics | n | (%) | Progressionc | HRd | 95% CI (HR) | PFSe |
|---|---|---|---|---|---|---|
| Total | 115 | (100.0) | 97 | |||
| Age at diagnosis | 0.21 | |||||
| <60 years | 53 | (46.1) | 47 | 1 | ||
| ≥60 years | 62 | (53.9) | 50 | 0.77 | [0.52; 1.15] | |
| Gender | 0.14 | |||||
| Female | 26 | (22.6) | 18 | 1 | ||
| Male | 89 | (77.4) | 79 | 1.47 | [0.87; 2.45] | |
| Tobaccoa | 0.007 | |||||
| No | 15 | (13.6) | 8 | 1 | ||
| Yes | 95 | (86.4) | 85 | 2.63 | [1.27; 5.45] | |
| Alcoholb | 0.33 | |||||
| No | 37 | (42.5) | 28 | 1 | ||
| Yes | 50 | (57.5) | 45 | 1.27 | [0.79; 2.03] | |
| HPV status | 0.007 | |||||
| Negative | 100 | (87.0) | 88 | 1 | ||
| Positive | 15 | (13.0) | 9 | 0.4 | [0.2; 0.8] | |
| AJCC stage | 0.13 | |||||
| Stage I–II | 16 | (13.9) | 14 | 1 | ||
| Stage III | 24 | (20.9) | 17 | 0.56 | [0.27; 1.14] | |
| Stage IV | 75 | (65.2) | 66 | 0.94 | [0.53; 1.69] | |
| Tumor location | 0.67 | |||||
| Oral cavity | 33 | (28.7) | 29 | 1 | ||
| Oropharynx | 50 | (45.5) | 41 | 0.74 | [0.46; 1.20] | |
| Larynx | 15 | (13.0) | 12 | 0.87 | [0.44; 1.71] | |
| Hypopharynx | 8 | (7.00) | 8 | 1.15 | [0.53; 2.53] | |
| Other | 9 | (7.80) | 7 | 0.98 | [0.43; 2.25] | |
| Treatment setting | NAf | NAf | NAf | |||
| Cetuximab in first-line recurrent setting | 77 | (67.0) | 72 | |||
| Cetuximab + radiotherapy | 38 | (33.0) | 25 | |||
Bold values are statistically significant. aInformation available for 110 patients; binformation available for 87 patients; cprogression data collected until June 2016; dHR estimated by non-adjusted Cox proportional hazards model; eP value of the log-rank test; fNot applicable as the clinical setting is different. HR, hazard ratio; HNSCC, head and neck squamous cell carcinoma; PFS, progression-free survival.